All News

Convention1.jpg

EULAR 2023: Featured Industry Presentations

Jack Cush, MD

EULAR 2023 opens tomorrow, Wednesday May 31st, with hundreds of novel presentations and pivotal clinical trials, many being featured industry sponsored clinical trials and research on their novel agents. Below is a collection of the featured abstracts, and presentation times from EULAR

Read Article
RheumNow Podcast square

3-4-5 Rule (5.26.2023)

Jack Cush, MD

Dr. Jack Cush reviews more than a dozen news, journal articles and RNL highlights from this past week on RheumNow.com.

Read Article
Rheumatoid,RA,nodules,damage

Prevalence of Psoriatic Arthritis, Spondyloarthritis and Rheumatoid Arthritis in Norway

Jack Cush, MD

Recent reports have suggested a rising and unrecognized number of patients with psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) compared to rheumatoid arthritis (RA).

Read Article
NSAIDs.pills_.caps_.jpg

NSAID Prescribing Decreasing

Jack Cush, MD

Multinational metanalyses of data between 1989 and 2022 shows that NSAID prescriptions have decreased over time, and differs according to geographical locations.

Read Article
SI AS SpA ACR

ICYMI: Spondyloarthritis Innovations

Robert Chao, MD

The second day of RheumNow Live 2023 held in March ended with a focus on axial spondyloarthritis, especially on the evaluation of the definition of the disease, the inheritance of it, and of course the treatment of it.

Read Article
PSA068.jpg

Disappointing Secondary Use of Newer Therapies in Psoriatic Arthritis

Jack Cush, MD

Analysis of patient data from five Nordic registries shows that the uptake of newer biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) in psoriatic arthritis (PsA) was mainly in biologic-experienced patients.

Read Article
There are lots of reasons why axSpA treatments fail for patients. And as rheumatologists, we can’t just prescribe and walk away - we need to address each in turn, for our patients’ sake #EULAR2023 @RheumNow https://t.co/hzo57BaEXw
David Liew drdavidliew ( View Tweet)
Vedolizumab (VED) doesnt help SpA. Study of 39 IBD, half on VED, 17 w/ SpA (7 axial). 14 w/ periph. arthritis before VED, only 3 improved w/ VED. 3 pts on VED developed new arthritis/aglas. 6 Pts stopped for SpA (2) or IBD (4) worsening. https://t.co/8BMTmJqhPq https://t.co/BOMsk38KB2

Links:

Dr. John Cush RheumNow ( View Tweet)
UK Biobank cohort study (n=361,952) assessed BMI effects on rheumatic Dz risk. Higher BMI incr odds of RA (IRR=1.52), OA (IRR=1.49), PsA (IRR=1.80), gout (1.73), SpA(1.34); more pronounced in women for both gout and psoriatic arthropathy https://t.co/eLeeShSSv1 https://t.co/IjWF2EPqOR

Links:

Dr. John Cush RheumNow ( View Tweet)
PREVENT study looked at Xray progression in 438 nr-axSpA pts given PBO or secukinumab. At baseline there was little SI damage & at 2 yrs no SI progression (− 0.04 mSASSS) or spinal inflammation in both groups. https://t.co/3EgnK2rWgb https://t.co/z5umUhpViF

Links:

Dr. John Cush RheumNow ( View Tweet)
MRI study of SI jts in axSpA 196 pts shows w/ increasing bone marrow edema of SI, SI damage is likely. BME each quadrant incr odds: sclerosis (OR:1.9), erosions (1.9). BME lead to 5 yr SIJ damage if fluctuating (OR:5.6) or persistent (OR:7.5) https://t.co/Dkbcij5Uhv https://t.co/x83kErVb1E

Links:

Dr. John Cush RheumNow ( View Tweet)
Save the date! We'll be tuning in live from Milan for EULAR '23. Count on us for: -KOL perspective videos -Clinical Trial Highlights -Daily Faculty Recaps -Live Streaming and more! https://t.co/9uKnDTynfk
Dr. John Cush RheumNow ( View Tweet)
⚠️Beware not all bone marrow oedema =#AxSpA on MRI ! Signal seen in 17% volunteers at SIJs @DrPoddubnyy #RNL2023 https://t.co/xTKuSRXK72 https://t.co/c09QjSkJBP

Links:

Dr. John Cush RheumNow ( View Tweet)
Dennis Poddubnyy #RNL2023 MRI sequences for axSpA: Semi-coronal- T1 weighted, T2 STIR, T1 weighted w fat suppression Semi-axial- T2 STIR @RheumNow https://t.co/aidLu7GcQH https://t.co/YOrboYl6pW

Links:

Dr. John Cush RheumNow ( View Tweet)
Dr. Deodhar reminds us of his "3,4,5 rule" for diagnosing AS. *Erosions in 3 or more SIJ quadrants *BME in 4 or more SIJ quadrants *Fat lesions in 5 of more SIJ quadrants #RNL2023 @RheumNow https://t.co/T9iWLcNL8b https://t.co/BskCNz9Klj

Links:

Dr. John Cush RheumNow ( View Tweet)
AxSpA is primarily a genetic disease - clusters in families, especially HLA-B27+ first degree relatives - genetic testing for asymptomatic relatives not recommended @RheumNow #RNL2023 https://t.co/WeNApLE5to https://t.co/zDzHfdmpCG

Links:

Dr. John Cush RheumNow ( View Tweet)
Risk of familial AS is 19.4%, Reveille #RNL2023 ⁦@RheumNow⁩ https://t.co/7CzaXgqkPG https://t.co/KrmKGblVmd

Links:

Dr. John Cush RheumNow ( View Tweet)
"50 years ago in April we discovered HLA B27." Dr. Reveille #RNL2023 @RheumNow

Dr. John Cush RheumNow ( View Tweet)

Bimekizumab is a dual IL-17A and IL-17F inhibitor, for nr-axSpA and AS - it works but is it different from existing IL-17i? - appears to work well in TNFi-inadequate responders - are TNFi-IR pts immunologically different? #RNL2023 https://t.co/bHboX3Xz6M https://t.co/kCa9MbFdxs

Links:

Dr. John Cush RheumNow ( View Tweet)
Have a Rheumatology question or case for Jack Cush? Record it here and we'll feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. https://t.co/0mC7PxF0DU https://t.co/klbnwjcPbM

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×